Watch the 22 sessions from SOSV Climate Tech Summit!

Intrinsic Medicine (fka Lupa Bio)

Developing the next generation of essential, disease-modifying medicines

Team

Jason Ferrone

President and Co-Founder

Alex Martinez

CEO & Co-Founder

Company details

Lupa Bio is developing a new drug based on a sugar found in human milk to treat inflammatory diseases. Because of its origins in human milk it has unprecedented safety, backed by human and animal data, by virtue of a mechanism that doesn’t rely on suppressing the immune system which is what causes many of the side effects seen with today’s drugs. Because the uncontrolled inflammatory response is responsible for the severe symptoms and deaths associated with COVID-19 infection, Lupa Bio is evaluating the utility of its drug to reduce severity of symptoms of the infection in milder and moderate cases as well as in the severe Cytokine Storm Syndromes cases. Lupa Bio has completed a positive Pre-IND meeting with the FDA and is working to submit an IND this year to enable rapidly advancing into clinical studies.

Get In Touch with Intrinsic Medicine (fka Lupa Bio)

Please tell us a little bit about yourself and why you'd like to get connected. Intrinsic Medicine (fka Lupa Bio) + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden
* If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.